Abstract: Previous reports suggest race/ethnic and sex heterogeneity in the association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma (PPARG) gene and cognitive decline. Tests of verbal memory, processing speed, and verbal fluency and a composite global Z-score were used to assess cognitive performance longitudinally in a large (n = 11,620) biracial cohort of older adults in the Atherosclerosis Risk in Communities Neurocognitive Study from midlife to older age. Linear mixed models were used to estimate associations between the Ala12 allele and cognitive performance over 20 years of follow-up. Heterogeneity was present for rate of cognitive decline as measured by the global Z-score by race, sex, and Ala12 allele status (P = 0.01 for 4-way interaction term: race×sex×time×Ala12 carrier status). Stratified analysis showed a significantly increased rate of global cognitive decline over the 20-year follow-up for carriers of the Ala12 allele compared with noncarriers among black male individuals (−0.92 SD decline vs. −0.57 SD; P = 0.02) but not among black female, white male, or white female individuals. Decline in global cognitive function among black male Ala12 carriers was primarily driven by decline in verbal memory. Our data underscore the context-dependent association between the Pro12Ala polymorphism and cognitive decline, specifically race/ethnic background and sex.
R eports linking metabolic dysfunction to cognitive decline and late-onset Alzheimer disease 1 have led to the investigation of genes involved in lipid and glucose metabolism as potential susceptibility loci for cognitive decline. The peroxisome proliferator-activated receptor gamma (PPARG) gene plays a key role in lipid metabolism and insulin sensitivity and has been shown in animal models to regulate components of amyloid β metabolism, 2 a proposed key causative factor in Alzheimer disease. The common Pro12Ala (C→G, rs1801282) polymorphism in the PPARG gene is responsible for a Pro to Ala transition in codon 12.
Since PPARG is a master transcriptional regulator involved in the expression of numerous genes, there is potential for complex interactions between the Pro12Ala polymorphism and other genetic and/or environmental factors on cognitive decline. Two cohort studies among older adults have reported comparable ethnicity-specific and sex-specific findings regarding the association between the Pro12Ala genotype and cognitive performance. 3, 4 Reports of the association of the Pro12Ala polymorphism with cognitive function that have not considered combined race/ ethnic and sex interactions have yielded conflicting or nonsignificant results. [5] [6] [7] [8] [9] [10] [11] [12] In the current study, we examined the relationship between Ala12 allele carrier status with cognitive decline in the large, biracial Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) cohort, followed over 20 years from midlife to older age. We hypothesized a priori that there would be significant interactions between Ala12 carrier status and cognitive decline with race and sex.
METHODS

Study Population
Participants were enrolled in the ARIC, which is a population based, prospective cohort study of cardiovascular disease in black and white adults from 4 US communities: Washington County MD, Forsyth County NC, Jackson MS, and suburban Minneapolis MN. Participants were seen beginning in 1987 to 1989. Cognitive function was evaluated at visit 2 (1990 to 1992), visit 4 (1996 to 1998), and visit 5 (2011 to 2013) as part of ARIC-NCS. Subsamples of the cohort also underwent cognitive testing at visit 3 (1993 to 1995) , and as part of 2 ancillary studies in 2004 to 2006 and 2005 to 2006, providing cognitive data at 6 time periods over a follow-up of 23 years. Details of the ARIC sampling frame and recruitment have been published elsewhere. 13 Baseline for the present analysis was visit 2 when cognitive data were first collected. Among the 14,348 participants who attended visit 2, we excluded participants whose Pro12Ala genotyping was unavailable (n = 2574) and those missing all 3 standardized cognitive test scores (n = 154), giving a final sample size of 11,620 participants at baseline (81% of the visit 2 sample). Compared with those included in this analysis, participants who were excluded were more likely (P < 0.05 for each comparison) to be black (39% vs. 22%), have prevalent diabetes (18% vs. 14%), have a history of stroke (2.5% vs. 1.8%), have a higher BMI (28.2 vs. 27.9 kg/m 2 ), and have less than a college education (67% vs. 62%) but were not significantly different (P > 0.05 for each comparison) in age (mean age = 57.1 vs. 57.0 y), sex (44.7% vs. 44.6% male individuals), waist circumference (98.3 vs. 97.9 cm), and APOE ε4 status (32% vs. 31%). Local institutional review boards approved the ARIC protocol, and all participants gave informed consent.
Cognitive Function Tests
Delayed word recall test (DWRT), digit symbol substitution test (DSST), and word fluency test (WFT) were used to assess cognitive performance and were summarized with a global Z-score. Protocols for the neurocognitive test battery were standardized and administered in the same sequence by trained examiners.
The DWRT is a test of verbal learning and recent memory. 14 Participants were asked to learn 10 common nouns by using each in a sentence. After a 5-minute filled delay, participants had 60 seconds to recall the words. The score for the DWRT is the number of words recalled.
The DSST of the Wechsler Adult Intelligence ScaleRevised 15 is a test of executive function and processing speed. Participants were asked to translate numbers to symbols using a key. The score is the count of numbers correctly translated to symbols in 90 seconds.
The WFT is a test of executive function and language. Participants were asked to generate as many words as possible beginning with each of the letters F, A, and S. The WFT score is the total number of words generated across the 3 letters in 60 seconds. 16 To facilitate comparison across cognitive tests, Z-scores standardized to visit 2 were calculated for each test by subtracting each participant's test score at each visit from the visit 2 mean and dividing by the visit 2 SD. A composite global cognitive Z-score was calculated by averaging the Z-scores of the 3 tests, and then standardized to visit 2 using the global Z mean and global Z SD from visit 2. Thus, a Z-score of −1 would describe cognitive performance that is 1 SD below the mean score at visit 2.
Pro12Ala Genotyping
The Pro12Ala single nucleotide polymorphism in the study participants was genotyped at the Broad Institute (Cambridge, Massachusetts) using the Affymetrix GeneChip SNP Array 6.0 and the Birdseed calling algorithm. 17 These data were extensively quality-controlled according to accepted standards, 18 including checks for genetic outliers via average identity-by-state statistics and EIGENSTRAT-generated principal components. 19 The Pro12Ala (rs1801282) variant was directly measured; we imputed the genotypes for missing values ( ≤ 5% of the sample) by exploiting a scaffold containing all variants with ethnic-specific missing rates ≤ 0.05, minor allele frequencies ≥ 0.01, and Hardy-Weinberg Equilibrium tests > 10
After prephasing with ShapeIt (v1.r532), we used IMPUTE2 and the 1000 Genomes haplotypes-phase I integrated variant set release (version 3) reference panel (NCBI Build 37) to impute the missing genotypes. 20, 21 Covariates All covariates used in the regression models were assessed during visit 2 except education, race, and sex, which were assessed during ARIC visit 1. The following covariates were evaluated as confounders: age, education (< high school; high school, high school equivalent, or vocational school; college, graduate, or professional school), waist circumference (cm), history of stroke (yes/no), apolipoprotein E (APOE) ε4 genotype (0/at least 1 ε4 allele), and diabetes (self-reported physician diagnosis, diabetes medication use, or HbA1c ≥ 6.5%).
Statistical Analysis
Participants were dichotomized into those who carried at least 1 copy of the alanine variant (Ala12+) at rs1801282 and those who did not (Ala12−). Time was modeled as years of follow-up from the baseline visit. Linear mixed models were used to estimate associations between the Ala12 allele category and cognitive change and to account for the within-person correlations of test scores arising from the repeated measures across time. To investigate our primary aim, we tested for effect modification between Ala12 carrier status, race, and sex with cognitive decline by adding interaction terms to the models; specifically, we included a 4-way interaction term (race×sex×Ala12 carrier status×-time), along with the corresponding 3-way and 2-way interaction terms, to the model.
We also tested for interactions of Ala12 allele status with education, waist circumference, history of stroke, APOE ε4 genotype, and diabetes in relation to cognitive decline by including interaction terms to the models. Statistical analyses were performed using PC-SAS (version 9.4).
We conducted 2 sets of sensitivity analyses. First, although visual inspection of a superimposed locally weighted scatterplot smoother curve that was fitted to the data suggested a linear relationship between cognitive decline and time, we included linear spline terms in the model and, in a separate model, included a quadratic term for time to account for potential nonlinearities. In the second sensitivity analysis, we investigated possible bias in our results attributable to informative dropout during the study period by incorporating joint modeling of longitudinal and survival data. Thorough methodological explanations of joint models that have been previously published. 22, 23 Briefly, whereas, traditional mixed models cannot account for survival outcomes, and survival models often do not account for outcomes with repeated measures, joint models determine the joint association of a risk factor both with survival outcomes and with repeated measurements. Applied to our analysis, such models allow us to make inferences about the association between Ala12 and longitudinal cognitive changes, while also accounting for the possibility that participants' likelihood of not returning to later ARIC examination visits, caused by death or onset of dementia, may be associated with their Ala12 carrier status.
RESULTS
Among the 11,620 participants included in our analysis, 22% (n = 2536) were black and 45% (n = 5185) were male. Baseline age ranged from 46 to 70 years (mean = 57 y; SD = 5.6). Maximum follow-up was 23.5 years; of the 84.6% participants with at least 1 visit beyond visit 2, the median follow-up time was 19.2 (interquartile range, 6.0-21.0) years. Black study participants were much less likely to be an Ala12 carrier than white participants (3.7% vs. 22.8%, P < 0.0001). The Ala12 allele frequency in the black study population was 1.9% and the genotype frequencies were in agreement with Hardy-Weinberg expectations (P = 0.92). The Ala12 frequency among the white sample was 12.3%, however, there was moderate statistical support that the genotype counts differed from the expectations of HardyWeinberg equilibrium (P = 0.05).
Among the 915 black male individuals, Ala12 carriers had a significantly larger waist circumference than the noncarriers but there were no differences in age, education, APOE ε4 carrier status, diabetes prevalence, history of stroke, or body mass index at the study baseline (Table 1) . Among the 1621 black female individuals, Ala12 carriers were less likely to have diabetes than Ala12 noncarriers but there were no significant differences in age, education, APOE ε4 carrier status, history of stroke, body mass index, or waist circumference at the study baseline. Among the 4270 white male or the 4814 white female individuals, there were no significant differences in baseline characteristics by Ala12 status. 17 Heterogeneity was present for rate of cognitive decline as measured by changes in the global Z-score among race, sex, and Ala12 allele status (P = 0.01 for 4-way interaction term: race×sex×time×Ala12 carrier status) and for the DWRT (P = 0.01 for the 4-way interaction term). Table 2 shows the 20-year cognitive decline (Z-score) associated with Ala12 allele carrier status, stratified by race/ethnicity and sex for each cognitive test and adjusted for age and education. Among the black male individuals, there was a significantly greater rate of cognitive decline in the global Z-score among Ala12+ black male individuals compared with Ala12-black male individuals (−0.92 SD decline vs. −0.57 SD). The unadjusted rates were also significantly greater among black male Ala12 carriers and noncarriers (Fig. 1A) . There was no association of Ala12 carrier status with the rate of cognitive decline among black female, white male, or white female individuals for any of the cognitive tests, with or without covariate adjustment.
Among the black male individuals, there were no significant interactions between Ala12 carrier status and education, waist circumference, history of stroke, APOE ε4 genotype, or diabetes status on global Z-score over time (P > 0.25 for each test). Because of the reduced sample size in the race-stratified and sex-stratified analyses, we examined the potential confounders and possible mediators of APOE ε4 status, waist circumference, diabetes status, and history of stroke at baseline by adding them individually to the model which included age and education. None of these covariates altered the significantly greater rate of decline for black male Ala12 carriers compared with black male noncarriers. Similar results were also observed for black male Ala12 carriers compared with noncarriers in the DWRT scores (Fig. 1B) , but not for the DSST or the WFT, with or without adjustment for the potential confounders.
Sensitivity analyses from models with linear spline terms and models that included a quadratic term for time supported the significant association observed in our main analysis between Ala12 carrier status and accelerated decline among black male Ala12 carriers compared with black male noncarriers. The sensitivity analysis using joint models to account for the possibility of differential study dropout between the Ala12 carrier groups also supported the statistically significant association between Ala12 carrier status and accelerated decline in cognitive global Z-scores (P = 0.03 for time×Ala12 interaction), and a marginal association in DWRT scores (P = 0.07 for time×Ala12 interaction) among black male individuals. There was no statistically significant relationship between Ala12 carrier status and cognitive decline among black female, white male, or white female individuals in the sensitivity analyses.
DISCUSSION
In this cohort of older black and white adults followed for 20 years with repeated cognitive assessments, there was an increased rate of cognitive decline for carriers of the Ala12 allele compared with noncarriers among black male individuals but not among black female individuals or among white male or female individuals. The inclusion of standard risk factors for cognitive impairment and potential mediators in analytic models did not significantly reduce the estimated effect of the Ala12 allele. Black male Ala12 carriers experienced an additional 0.35 Z-score decline [95% confidence interval (CI): −0.62 to −0.08] in global cognition over the 20-year follow-up compared with black male individuals without the allele. This estimated effect was similar to the magnitude estimated for baseline diabetes, to the extent that black male individuals with diabetes at baseline experienced an additional 0.33 Z-score decline (95% CI: −0.46 to −0.19) in global cognition compared with black male individuals without diabetes over the follow-up period. The observed association of the Ala12 allele with decline in global cognitive function among the black male individuals was primarily driven by decline in verbal memory scores, where there was an additional 0.61 Z-score decline (95% CI: −1.21 to −0.01) for verbal memory for black male Ala12 carriers compared with black male noncarriers.
Other male-restricted associations have been reported with the Pro12Ala polymorphism. [24] [25] [26] [27] [28] Recent studies suggest that genetic variation of many species affects anatomic, physiological, and metabolic traits differently in male and female individuals, suggesting that sex might interact with genotype in a manner similar to other environmental factors. 29 Sex-specific effects of genes involved in the regulation of lipid and glucose metabolism such as PPARG could be attributed to hormonal differences, such as plasma estrogens. Adipose tissue is also a target for sex steroids and there is evidence to show a bidirectional signaling cross-talk between PPARG and estrogen receptors. 30 Integrating the evidence suggesting a role for estrogen in the regulation of adipose tissue and glucose metabolism 31 with the evidence that PPARG can adapt gene expression to various lipid signals 32 provides a potential biological link to the sexspecific results of our study.
Although a phenotypic trait resulting from a specific genotype may vary between race/ethnic groups because of interactions with environmental and/or other genetic factors, we were unable to identify specific biological mechanisms that may underlie the race-specific observations in our study. The substitution of alanine for proline in the Pro12Ala polymorphism has been shown to moderately reduce transcriptional activity of PPARG. 33 It has been demonstrated in animal studies that PPARG activation promotes amyloid β clearance in the brain. 2 A reduction in transcription activity could potentially reduce amyloid β clearance and, as a consequence, increase amyloid β peptide deposition, which is a hallmark characteristic of Alzheimer dementia.
Although our study is the first, to the best of our knowledge, to investigate the cross-classification of both race and sex among a cohort of older black participants in the association of the Pro12Ala polymorphism with cognitive decline, our findings are consistent with 2 prior studies that have reported a similar relationship. Among a large cohort of older Mexican-Americans, an increased rate of cognitive impairment was reported only among male carriers of the Ala12 allele compared with male noncarriers (adjusted hazard ratio = 2.7, 95% CI: 1.4-5.2). 4 In a bi-ethnic cohort study, there was significantly greater cognitive decline among Mexican-American male Ala12 carriers compared with Mexican-American male noncarriers but decline did not differ between Mexican-American female, white male, or white female carriers and noncarriers. 3 Our data underscore the context-dependent association between the Pro12Ala polymorphism and cognitive decline, specifically race/ethnic background and sex.
The present study has several strengths including a longitudinal assessment of cognitive status in a large cohort with a long follow-up period. Examination of cognitive decline as our primary outcome as opposed to dementia or cognitive performance assessed cross-sectionally substantially reduces confounding attributable to education. 34, 35 Further, cognitive decline is a risk factor for incident dementia 36 and is a required component of the dementia syndrome. 37 The sensitivity analysis suggests that our findings seem to be robust to possible bias from differential study dropout. A limitation is that the small number of individuals who were homozygous for the Ala12 allele restricted our ability to investigate a doseresponse relationship. Selection bias caused by loss of followup is of potential concern; however, it is known that selection bias occurs when study responses are jointly dependent on exposure and disease outcome. Although follow-up participation may be influenced by cognitive status in our study, it is unlikely that exposure status (Pro12Ala genotype) would influence participation.
In summary, our results indicate a significant association between the Pro12Ala genotype of PPARG and an increased rate of cognitive decline among older black male individuals but not among black female, white male, or white female individuals. The mechanisms underlying these associations will require additional study.
